Frank J Gonzalez

List of Publications by Year
in descending order

397 papers	46,069 citations	1043 113 h-index	2446 197 g-index
405 all docs	405 docs citations	405 times ranked	41725 citing authors

#	Article	IF	Citations
1	Intestinal peroxisome proliferatorâ€activated receptor Î±â€fatty acidâ€binding protein 1 axis modulates nonalcoholic steatohepatitis. Hepatology, 2023, 77, 239-255.	3.6	36
2	Caffeic acid phenethyl ester suppresses intestinal FXR signaling and ameliorates nonalcoholic fatty liver disease by inhibiting bacterial bile salt hydrolase activity. Acta Pharmacologica Sinica, 2023, 44, 145-156.	2.8	12
3	YAPâ€TEAD mediates PPAR Î±â€“induced hepatomegaly and liver regeneration in mice. Hepatology, 2022, 75, 74-88.	3.6	35
4	Cardiomyocyte peroxisome proliferator-activated receptor Î± is essential for energy metabolism and extracellular matrix homeostasis during pressure overload-induced cardiac remodeling. Acta Pharmacologica Sinica, 2022, 43, 1231-1242.	2.8	11
5	Intestinal farnesoid X receptor signaling controls hepatic fatty acid oxidation. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159089.	1.2	2
6	The role of mouse and human peroxisome proliferator-activated receptor-Î± in modulating the hepatic effects of perfluorooctane sulfonate in mice. Toxicology, 2022, 465, 153056.	2.0	6
7	Withaferin A alleviates ethanol-induced liver injury by inhibiting hepatic lipogenesis. Food and Chemical Toxicology, 2022, 160, 112807.	1.8	6
8	Crosstalk between CYP2E1 and PPARÎ± substrates and agonists modulate adipose browning and obesity. Acta Pharmaceutica Sinica B, 2022, 12, 2224-2238.	5.7	10
9	Disruption of peroxisome proliferator-activated receptor Î± in hepatocytes protects against acetaminophen-induced liver injury by activating the IL-6/STAT3 pathway. International Journal of Biological Sciences, 2022, 18, 2317-2328.	2.6	3
10	Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis. Cell Host and Microbe, 2022, 30, 289-300.	5.1	208
11	Gene repression through epigenetic modulation by PPARA enhances hepatocellular proliferation. IScience, 2022, 25, 104196.	1.9	15
12	HNF4A modulates glucocorticoid action in the liver. Cell Reports, 2022, 39, 110697.	2.9	10
13	Creatine riboside is a cancer cellâ€“derived metabolite associated with arginine auxotrophy. Journal of Clinical Investigation, 2022, 132, .	3.9	4
14	Withaferin A alleviates fulminant hepatitis by targeting macrophage and NLRP3. Cell Death and Disease, 2021, 12, 174.	2.7	20
15	FXR-Deoxycholic Acid-TNF-Î± Axis Modulates Acetaminophen-Induced Hepatotoxicity. Toxicological Sciences, 2021, 181, 273-284.	1.4	14
16	The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 335-347.	8.2	167
17	Novel Strategy for Mining and Identification of Acylcarnitines Using Data-Independent-Acquisition-Based Retention Time Prediction Modeling and Pseudo-Characteristic Fragmentation Ion Matching. Journal of Proteome Research, 2021, 20, 1602-1611.	1.8	3
18	Targeting Xenobiotic Nuclear Receptors PXR and CAR to Prevent Cobicistat Hepatotoxicity. Toxicological Sciences, 2021, 181, 58-67.	1.4	12

#	Article	IF	Citations
19	Testosterone Metabolite 6Î²â€Hydroxytestosterone Contributes to Angiotensin IIâ€Induced Abdominal Aortic Aneurysms in Apoe ^{â€“/â€“} Male Mice. Journal of the American Heart Association, 2021, 10, e018536.	1.6	6
20	Manassantin B attenuates obesity by inhibiting adipogenesis and lipogenesis in an AMPK dependent manner. FASEB Journal, 2021, 35, e21496.	0.2	1
21	Suppressing the intestinal farnesoid X receptor/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis. Journal of Clinical Investigation, 2021, 131, .	3.9	50
22	Feeding-induced resistance to acute lethal sepsis is dependent on hepatic BMAL1 and FXR signalling. Nature Communications, 2021, 12, 2745.	5.8	13
23	Oleuropein-Induced Acceleration of Cytochrome P450â€“Catalyzed Drug Metabolism: Central Role for Nuclear Receptor Peroxisome Proliferator-Activated Receptor Î±. Drug Metabolism and Disposition, 2021, 49, 833-843.	1.7	11
24	Species Differences between Mouse and Human PPARÎ± in Modulating the Hepatocarcinogenic Effects of Perinatal Exposure to a High-Affinity Human PPARÎ± Agonist in Mice. Toxicological Sciences, 2021, 183, 81-92.	1.4	12
25	Diminished Hepatocarcinogenesis by a Potent, High-Affinity Human PPARÎ± Agonist in PPARA-Humanized Mice. Toxicological Sciences, 2021, 183, 70-80.	1.4	8
26	Intestinal MYC modulates obesity-related metabolic dysfunction. Nature Metabolism, 2021, 3, 923-939.	5.1	27
27	Myelocytomatosisâ€Protein Arginine Nâ€Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma. Hepatology, 2021, 74, 1932-1951.	3.6	28
28	Mutant Idh2 Cooperates with a NUP98-HOXD13 Fusion to Induce Early Immature Thymocyte Precursor ALL. Cancer Research, 2021, 81, 5033-5046.	0.4	7
29	Metabolic map of the antiviral drug podophyllotoxin provides insights into hepatotoxicity. Xenobiotica, 2021, 51, 1047-1059.	0.5	5
30	Feedback repression of PPARÎ± signaling by Let-7 microRNA. Cell Reports, 2021, 36, 109506.	2.9	12
31	Deficiency of peroxisome proliferator-activated receptor Î± attenuates apoptosis and promotes migration of vascular smooth muscle cells. Biochemistry and Biophysics Reports, 2021, 27, 101091.	0.7	2
32	The pathophysiological function of non-gastrointestinal farnesoid X receptor. , 2021, 226, 107867.		26
33	6Î²-Hydroxytestosterone Promotes Angiotensin II-Induced Hypertension via Enhanced Cytosolic Phospholipase A ₂ Î± Activity. Hypertension, 2021, 78, 1053-1066.	1.3	0
34	Lysosomal SLC46A3 modulates hepatic cytosolic copper homeostasis. Nature Communications, 2021, 12, 290.	5.8	19
35	St. Johnâ€™s Wort alleviates dextran sodium sulfateâ€induced colitis through pregnane X receptorâ€dependent NFÎºB antagonism. FASEB Journal, 2021, 35, e21968.	0.2	9
36	Polyamine metabolism links gut microbiota and testicular dysfunction. Microbiome, 2021, 9, 224.	4.9	41

#	Article	IF	Citations
37	Withaferin A in the treatment of liver diseases: progress and pharmacokinetic insights. Drug Metabolism and Disposition, 2021, , DMD-MR-2021-000455.	1.7	8
38	A multiparametric organ toxicity predictor for drug discovery. Toxicology Mechanisms and Methods, 2020, 30, 159-166.	1.3	16
39	A trans-fatty acid-rich diet promotes liver tumorigenesis in HCV core gene transgenic mice. Carcinogenesis, 2020, 41, 159-170.	1.3	13
40	Propranolol is a mechanismâ€based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6â€transgenic mice: Effects on activity and drug responses. British Journal of Pharmacology, 2020, 177, 701-712.	2.7	11
41	Rutaecarpine inhibits KEAP1-NRF2 interaction to activate NRF2 and ameliorate dextran sulfate sodium-induced colitis. Free Radical Biology and Medicine, 2020, 148, 33-41.	1.3	73
42	Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. Acta Pharmaceutica Sinica B, 2020, 10, 3-18.	5.7	121
43	Comprehensive analysis of transcriptomics and metabolomics to understand triptolide-induced liver injury in mice. Toxicology Letters, 2020, 333, 290-302.	0.4	42
44	PPARÎ± mediates night neon light-induced weight gain: role of lipid homeostasis. Theranostics, 2020, 10, 11497-11506.	4.6	12
45	Dietary Restriction Suppresses Steatosis-Associated Hepatic Tumorigenesis in Hepatitis C Virus Core Gene Transgenic Mice. Liver Cancer, 2020, 9, 529-548.	4.2	16
46	Long non-coding RNA Gm15441 attenuates hepatic inflammasome activation in response to PPARA agonism and fasting. Nature Communications, 2020, 11, 5847.	5.8	52
47	MicroRNA-1291-5p Sensitizes Pancreatic Carcinoma Cells to Arginine Deprivation and Chemotherapy through the Regulation of Arginolysis and Glycolysis. Molecular Pharmacology, 2020, 98, 686-694.	1.0	21
48	Investigation on the metabolic characteristics of isobavachin in Psoralea corylifolia L. (Bu-gu-zhi) and its potential inhibition against human cytochrome P450s and UDP-glucuronosyltransferases. Journal of Pharmacy and Pharmacology, 2020, 72, 1865-1878.	1.2	10
49	Human CYP2D6 in the Brain Is Protective Against Harmine-Induced Neurotoxicity: Evidence from Humanized CYP2D6 Transgenic Mice. Molecular Neurobiology, 2020, 57, 4608-4621.	1.9	5
50	Celastrol ameliorates acute liver injury through modulation of PPARÎ±. Biochemical Pharmacology, 2020, 178, 114058.	2.0	24
51	Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice. Molecular Neurobiology, 2020, 57, 2509-2520.	1.9	9
52	PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice. International Journal of Molecular Sciences, 2020, 21, 2061.	1.8	268
53	Metabolism and disposition of corylifol A from Psoralea corylifolia: metabolite mapping, isozyme contribution, species differences and identification of efflux transporters for corylifol A-O-glucuronide in HeLa1A1 cells. Xenobiotica, 2020, 50, 997-1008.	0.5	7
54	Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western dietâ€“fed mice. Journal of Biological Chemistry, 2020, 295, 4733-4747.	1.6	37

#	Article	IF	Citations
55	SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis. Nature Communications, 2020, 11, 240.	5.8	78
56	6Î²-Hydroxytestosterone, a metabolite of testosterone generated by CYP1B1, contributes to vascular changes in angiotensin II-induced hypertension in male mice. Biology of Sex Differences, 2020, 11, 4.	1.8	13
57	Nuclear receptors and non-alcoholic fatty liver disease: An update. Liver Research, 2020, 4, 88-93.	0.5	15
58	Upregulation of BDNF and hippocampal functions by a hippocampal ligand of PPARÎ±. JCI Insight, 2020, 5, .	2.3	26
59	A metabolomic perspective of pazopanib-induced acute hepatotoxicity in mice. Xenobiotica, 2019, 49, 655-670.	0.5	21
60	Lipidomics reveal aryl hydrocarbon receptor (Ahr)-regulated lipid metabolic pathway in alpha-naphthyl isothiocyanate (ANIT)-induced intrahepatic cholestasis. Xenobiotica, 2019, 49, 591-601.	0.5	12
61	Dietary Intake Regulates the Circulating Inflammatory Monocyte Pool. Cell, 2019, 178, 1102-1114.e17.	13.5	254
62	Role of Metabolic Activation in Elemicin-Induced Cellular Toxicity. Journal of Agricultural and Food Chemistry, 2019, 67, 8243-8252.	2.4	23
63	Gut microbiotaâ€“bile acidâ€“interleukin-22 axis orchestrates polycystic ovary syndrome. Nature Medicine, 2019, 25, 1225-1233.	15.2	394
64	Glutathione deficiency-elicited reprogramming of hepatic metabolism protects against alcohol-induced steatosis. Free Radical Biology and Medicine, 2019, 143, 127-139.	1.3	18
65	Intestinal PPARÎ± Protects Against Colon Carcinogenesis via Regulation of Methyltransferases DNMT1 and PRMT6. Gastroenterology, 2019, 157, 744-759.e4.	0.6	111
66	Withaferin A Improves Nonalcoholic Steatohepatitis in Mice. Journal of Pharmacology and Experimental Therapeutics, 2019, 371, 360-374.	1.3	17
67	In utero exposure to di(2-ethylhexyl)phthalate suppresses blood glucose and leptin levels in the offspring of wild-type mice. Toxicology, 2019, 415, 49-55.	2.0	11
68	Keratin 23 Is a Peroxisome Proliferatorâ€Activated Receptor Alphaâ€“Dependent, MYCâ€Amplified Oncogene That Promotes Hepatocyte Proliferation. Hepatology, 2019, 70, 154-167.	3.6	25
69	Modulation of Lipid Metabolism by Celastrol. Journal of Proteome Research, 2019, 18, 1133-1144.	1.8	42
70	The Protective Roles of PPARÎ± Activation in Triptolide-Induced Liver Injury. Toxicological Sciences, 2019, 171, 1-12.	1.4	20
71	The Efflux Mechanism of Fraxetin-O-Glucuronides in UGT1A9-Transfected HeLa Cells: Identification of Multidrug Resistance-Associated Proteins 3 and 4 (MRP3/4) as the Important Contributors. Frontiers in Pharmacology, 2019, 10, 496.	1.6	12
72	Mechanism of the efflux transport of demethoxycurcumin-O-glucuronides in HeLa cells stably transfected with UDP-glucuronosyltransferase 1A1. PLoS ONE, 2019, 14, e0217695.	1.1	4

#	Article	IF	Citations
73	Hepatocyte peroxisome proliferator-activated receptor Î± regulates bile acid synthesis and transport. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 1396-1411.	1.2	33
74	Impaired clearance of sunitinib leads to metabolic disorders and hepatotoxicity. British Journal of Pharmacology, 2019, 176, 2162-2178.	2.7	27
75	Hepatic metabolic adaptation in a murine model of glutathione deficiency. Chemico-Biological Interactions, 2019, 303, 1-6.	1.7	10
76	The concomitant loss of <scp>APC</scp> and <scp>HNF</scp>4Î± in adult hepatocytes does not contribute to hepatocarcinogenesis driven by Î²â€catenin activation. Liver International, 2019, 39, 727-739.	1.9	3
77	Hepatocyte Peroxisome Proliferatorâ€"Activated Receptor Î± Enhances Liver Regeneration after Partial Hepatectomy in Mice. American Journal of Pathology, 2019, 189, 272-282.	1.9	23
78	A systemic workflow for profiling metabolome and lipidome in tissue. Journal of Chromatography A, 2019, 1589, 105-115.	1.8	13
79	Celastrol Protects From Cholestatic Liver Injury Through Modulation of SIRT1-FXR Signaling. Molecular and Cellular Proteomics, 2019, 18, 520-533.	2.5	45
80	The role of hypoxia-inducible factors in metabolic diseases. Nature Reviews Endocrinology, 2019, 15, 21-32.	4.3	254
81	Pregnane X receptor activation potentiates ritonavir hepatotoxicity. Journal of Clinical Investigation, 2019, 129, 2898-2903.	3.9	32
82	Intestine farnesoid X receptor agonist and the gut microbiota activate Gâ€protein bile acid receptorâ€1 signaling to improve metabolism. Hepatology, 2018, 68, 1574-1588.	3.6	348
83	Fat-specific protein 27 is a novel target gene of liver X receptor Î±. Molecular and Cellular Endocrinology, 2018, 474, 48-56.	1.6	13
84	Targeted Metabolomics Reveals a Protective Role for Basal PPARÎ± in Cholestasis Induced by Î±-Naphthylisothiocyanate. Journal of Proteome Research, 2018, 17, 1500-1508.	1.8	17
85	Structure-Activity Relationships of the Main Bioactive Constituents of Euodia rutaecarpa on Aryl Hydrocarbon Receptor Activation and Associated Bile Acid Homeostasis. Drug Metabolism and Disposition, 2018, 46, 1030-1040.	1.7	21
86	PPARÎ± Mediates the Hepatoprotective Effects of Nutmeg. Journal of Proteome Research, 2018, 17, 1887-1897.	1.8	20
87	Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2Î± Inhibitor PT2385 In Vivo and In Vitro. Drug Metabolism and Disposition, 2018, 46, 336-345.	1.7	25
88	Chemical inhibition and stable knock-down of efflux transporters leads to reduced glucuronidation of wushanicaritin in UGT1A1-overexpressing HeLa cells: the role of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins (MRPs) in the excretion of glucuronides. Food and Function, 2018, 9, 1410-1423.	2.1	16
89	Metabolic profiling of corylin in vivo and in vitro. Journal of Pharmaceutical and Biomedical Analysis, 2018, 155, 157-168.	1.4	16
90	Metabolic map of osthole and its effect on lipids. Xenobiotica, 2018, 48, 285-299.	0.5	26

#	Article	IF	Citations
91	FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity. Journal of the American Society of Nephrology: JASN, 2018, 29, 118-137.	3.0	133
92	Metabolic adaptation to intermittent fasting is independent of peroxisome proliferator-activated receptor alpha. Molecular Metabolism, 2018, 7, 80-89.	3.0	20
93	Hepatic peroxisome proliferatorâ€activated receptor alpha mediates the major metabolic effects of Wyâ€14643. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1138-1145.	1.4	16
94	Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nature Medicine, 2018, 24, 1919-1929.	15.2	632
95	Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development. Hepatology Communications, 2018, 2, 1567-1582.	2.0	35
96	The roles of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated proteins (MRPs/ABCCs) in the excretion of cycloicaritin-3-O-glucoronide in UGT1A1-overexpressing HeLa cells. Chemico-Biological Interactions, 2018, 296, 45-56.	1.7	11
97	PPARÎ±-independent action against metabolic syndrome development by fibrates is mediated by inhibition of STAT3 signalling. Journal of Pharmacy and Pharmacology, 2018, 70, 1630-1642.	1.2	8
98	Cytochrome P450 1B1 Is Critical for Neointimal Growth in Wireâ€Injured Carotid Artery of Male Mice. Journal of the American Heart Association, 2018, 7, e010065.	1.6	6
99	Noncanonical farnesoid X receptor signaling inhibits apoptosis and impedes liver fibrosis. EBioMedicine, 2018, 37, 322-333.	2.7	32
100	Efflux excretion of bisdemethoxycurcuminâ€Oâ€glucuronide in UGT1A1â€overexpressing HeLa cells: Identification of breast cancer resistance protein (BCRP) and multidrug resistanceâ€associated proteins 1 (MRP1) as the glucuronide transporters. BioFactors, 2018, 44, 558-569.	2.6	8
101	Extrahepatic PPARÎ± modulates fatty acid oxidation and attenuates fasting-induced hepatosteatosis in mice. Journal of Lipid Research, 2018, 59, 2140-2152.	2.0	51
102	Metabolic alterations in triptolideâ€induced acute hepatotoxicity. Biomedical Chromatography, 2018, 32, e4299.	0.8	35
103	In vitrometabolic mapping of neobavaisoflavone in human cytochromes P450 and UDP-glucuronosyltransferase enzymes by ultra high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2018, 158, 351-360.	1.4	10
104	Glycyrrhizin Alleviates Nonalcoholic Steatohepatitis via Modulating Bile Acids and Meta-Inflammation. Drug Metabolism and Disposition, 2018, 46, 1310-1319.	1.7	64
105	Adipocyte-derived Lysophosphatidylcholine Activates Adipocyte and Adipose Tissue Macrophage Nod-Like Receptor Protein 3 Inflammasomes Mediating Homocysteine-Induced Insulin Resistance. EBioMedicine, 2018, 31, 202-216.	2.7	50
106	REVERBa couples the circadian clock to hepatic glucocorticoid action. Journal of Clinical Investigation, 2018, 128, 4454-4471.	3.9	70
107	Dual action of peroxisome proliferator-activated receptor alpha in perfluorodecanoic acid-induced hepatotoxicity. Archives of Toxicology, 2017, 91, 897-907.	1.9	19
108	Intestinal Farnesoid X Receptor Signaling Modulates Metabolic Disease. Digestive Diseases, 2017, 35, 178-184.	0.8	81

#	Article	IF	Citations
109	2-Methoxyestradiol Reduces Angiotensin IIâ€“Induced Hypertension and Renal Dysfunction in Ovariectomized Female and Intact Male Mice. Hypertension, 2017, 69, 1104-1112.	1.3	25
110	Editorâ€™s Highlight: Farnesoid X Receptor Protects Against Low-Dose Carbon Tetrachloride-Induced Liver Injury Through the Taurocholate-JNK Pathway. Toxicological Sciences, 2017, 158, 334-346.	1.4	17
111	Gender Differences in Bile Acids and Microbiota in Relationship with Gender Dissimilarity in Steatosis Induced by Diet and FXR Inactivation. Scientific Reports, 2017, 7, 1748.	1.6	103
112	Targeting nuclear receptors for the treatment of fatty liver disease. , 2017, 179, 142-157.		164
113	Glycyrrhizin and glycyrrhetinic acid inhibits alpha-naphthyl isothiocyanate-induced liver injury and bile acid cycle disruption. Toxicology, 2017, 386, 133-142.	2.0	32
114	Farnesoid X Receptor Regulation of the NLRP3 Inflammasome Underlies Cholestasis-Associated Sepsis. Cell Metabolism, 2017, 25, 856-867.e5.	7.2	258
115	Hepatocyte-specific PPARA expression exclusively promotes agonist-induced cell proliferation without influence from nonparenchymal cells. American Journal of Physiology - Renal Physiology, 2017, 312, G283-G299.	1.6	71
116	Potential role of CYP1B1 in the development and treatment of metabolic diseases. , 2017, 178, 18-30.		122
117	Activation of intestinal hypoxia-inducible factor 2Î± during obesity contributes to hepatic steatosis. Nature Medicine, 2017, 23, 1298-1308.	15.2	108
118	A Western diet-induced mouse model reveals a possible mechanism by which metformin decreases obesity. European Journal of Clinical Pharmacology, 2017, 73, 1337-1339.	0.8	3
119	Growth arrest and DNA damage-inducible 45Î± protects against nonalcoholic steatohepatitis induced by methionine- and choline-deficient diet. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 3170-3182.	1.8	36
120	Intermittent Fasting Promotes White Adipose Browning and Decreases Obesity by Shaping the GutÂMicrobiota. Cell Metabolism, 2017, 26, 672-685.e4.	7.2	427
121	Inhibition of JNK signalling mediates PPARÎ±â€dependent protection against intrahepatic cholestasis by fenofibrate. British Journal of Pharmacology, 2017, 174, 3000-3017.	2.7	38
122	An Intestinal Farnesoid X Receptorâ€“Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice. Diabetes, 2017, 66, 613-626.	0.3	151
123	PPARÎ± protects against trans -fatty-acid-containing diet-induced steatohepatitis. Journal of Nutritional Biochemistry, 2017, 39, 77-85.	1.9	29
124	Role of the lipid-regulated NF-ÎºB/IL-6/STAT3 axis in alpha-naphthyl isothiocyanate-induced liver injury. Archives of Toxicology, 2017, 91, 2235-2244.	1.9	31
125	Insulin Represses Fasting-Induced Expression of Hepatic Fat-Specific Protein 27. Biological and Pharmaceutical Bulletin, 2017, 40, 888-893.	0.6	7
126	In Vitro Glucuronidation of Wushanicaritin by Liver Microsomes, Intestine Microsomes and Expressed Human UDP-Glucuronosyltransferase Enzymes. International Journal of Molecular Sciences, 2017, 18, 1983.	1.8	15

#	Article	IF	Citations
127	Metabolic profiling by gas chromatography-mass spectrometry of energy metabolism in high-fat diet-fed obese mice. PLoS ONE, 2017, 12, e0177953.	1.1	46
128	Hepatic Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) regulates metabolism in mice. PLoS ONE, 2017, 12, e0186543.	1.1	4
129	Nuclear Receptor PPARÎ± Agonist Wy-14,643 Ameliorates Hepatic Cell Death in Hepatic IKKÎ²-Deficient Mice. Biomolecules and Therapeutics, 2017, 25, 504-510.	1.1	4
130	A lipidomics investigation into the intervention of celastrol in experimental colitis. Molecular BioSystems, 2016, 12, 1436-1444.	2.9	25
131	6Î²-Hydroxytestosterone, a Cytochrome P450 1B1-Testosteroneâ€“Metabolite, Mediates Angiotensin Iiâ€“Induced Renal Dysfunction in Male Mice. Hypertension, 2016, 67, 916-926.	1.3	19
132	Cytochrome P450 1B1 Contributes to the Development of Angiotensin Iiâ€“Induced Aortic Aneurysm in Male Apoeâ^'/â^' Mice. American Journal of Pathology, 2016, 186, 2204-2219.	1.9	12
133	Phosphorylation of Farnesoid X Receptor at Serine 154 Links Ligand Activation With Degradation. Molecular Endocrinology, 2016, 30, 1070-1080.	3.7	22
134	The antiandrogen flutamide is a novel aryl hydrocarbon receptor ligand that disrupts bile acid homeostasis in mice through induction of Abcc4. Biochemical Pharmacology, 2016, 119, 93-104.	2.0	23
135	An Intestinal Microbiotaâ€“Farnesoid X Receptor Axis Modulates Metabolic Disease. Gastroenterology, 2016, 151, 845-859.	0.6	254
136	Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans. Journal of Lipid Research, 2016, 57, 2130-2137.	2.0	221
137	Ligand activation of peroxisome proliferator-activated receptor-Î²/Î´ suppresses liver tumorigenesis in hepatitis B transgenic mice. Toxicology, 2016, 363-364, 1-9.	2.0	16
138	Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice. Hepatology, 2016, 64, 1072-1085.	3.6	121
139	Identification and characterization of PPARÎ± ligands in the hippocampus. Nature Chemical Biology, 2016, 12, 1075-1083.	3.9	63
140	Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism. MSystems, 2016, 1, .	1.7	95
141	PPARÎ± activation drives demethylation of the CpG islands of the Gadd45b promoter in the mouse liver. Biochemical and Biophysical Research Communications, 2016, 476, 293-298.	1.0	6
142	Chemogenetic disconnection of monkey orbitofrontal and rhinal cortex reversibly disrupts reward value. Nature Neuroscience, 2016, 19, 37-39.	7.1	121
143	Cytochrome P450 1B1 Contributes to the Development of Atherosclerosis and Hypertension in Apolipoprotein Eâ€“Deficient Mice. Hypertension, 2016, 67, 206-213.	1.3	35
144	Glycyrrhizin Protects against Acetaminophen-Induced Acute Liver Injury via Alleviating Tumor Necrosis Factor Â-Mediated Apoptosis. Drug Metabolism and Disposition, 2016, 44, 720-731.	1.7	54

#	Article	IF	Citations
145	HIF2 Î± Is an Essential Molecular Brake for Postprandial Hepatic Glucagon Response Independent of Insulin Signaling. Cell Metabolism, 2016, 23, 505-516.	7.2	42
146	Irinotecan (CPT-11)-induced elevation of bile acids potentiates suppression of IL-10 expression. Toxicology and Applied Pharmacology, 2016, 291, 21-27.	1.3	20
147	Mechanism of the development of nonalcoholic steatohepatitis after pancreaticoduodenectomy. BBA Clinical, 2015, 3, 168-174.	4.1	26
148	Persistent Organic Pollutants Modify Gut Microbiotaâ€“Host Metabolic Homeostasis in Mice Through Aryl Hydrocarbon Receptor Activation. Environmental Health Perspectives, 2015, 123, 679-688.	2.8	262
149	Regulation profile of phosphatidylcholines (PCs) and lysophosphatidylcholines (LPCs) components towards UDP-glucuronosyltransferases (UGTs) isoforms. Xenobiotica, 2015, 45, 197-206.	0.5	10
150	Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nature Communications, 2015, 6, 10166.	5.8	413
151	Steatogenesis in adult-onset type II citrullinemia is associated with down-regulation of PPARÎ±. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 473-481.	1.8	57
152	Therapeutic Efficacy of Wuzhi Tablet (Schisandra sphenanthera Extract) on Acetaminophen-Induced Hepatotoxicity through a Mechanism Distinct from N-Acetylcysteine. Drug Metabolism and Disposition, 2015, 43, 317-324.	1.7	33
153	Adipocyte-specific Disruption of Fat-specific Protein 27 Causes Hepatosteatosis and Insulin Resistance in High-fat Diet-fed Mice. Journal of Biological Chemistry, 2015, 290, 3092-3105.	1.6	77
154	Metabolic mapping of A3 adenosine receptor agonist MRS5980. Biochemical Pharmacology, 2015, 97, 215-223.	2.0	13
155	HMG-CoA Reductase Inhibitors Bind to PPARÎ± to Upregulate Neurotrophin Expression in the Brain and Improve Memory in Mice. Cell Metabolism, 2015, 22, 253-265.	7.2	122
156	Fat-Specific Protein 27/CIDEC Promotes Development of Alcoholic Steatohepatitis in Mice and Humans. Gastroenterology, 2015, 149, 1030-1041.e6.	0.6	114
157	6Î²-Hydroxytestosterone, a Cytochrome P450 1B1 Metabolite of Testosterone, Contributes to Angiotensin IIâ€“Induced Hypertension and Its Pathogenesis in Male Mice. Hypertension, 2015, 65, 1279-1287.	1.3	36
158	Inhibition of farnesoid X receptor signaling shows beneficial effects in human obesity. Journal of Hepatology, 2015, 62, 1234-1236.	1.8	28
159	Activation of peroxisome proliferator-activated receptor Î± stimulates ADAM10-mediated proteolysis of APP. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8445-8450.	3.3	116
160	Modulation of Colon Cancer by Nutmeg. Journal of Proteome Research, 2015, 14, 1937-1946.	1.8	44
161	Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 1242-1252.	1.8	95
162	GC-MS metabolomics on PPARÎ±-dependent exacerbation of colitis. Molecular BioSystems, 2015, 11, 1329-1337.	2.9	18

#	Article	IF	Citations
163	Transgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicity. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 869-881.	1.5	39
164	St. John's Wort Attenuates Colorectal Carcinogenesis in Mice through Suppression of Inflammatory Signaling. Cancer Prevention Research, 2015, 8, 786-795.	0.7	10
165	Bile acid signaling in lipid metabolism: Metabolomic and lipidomic analysis of lipid and bile acid markers linked to anti-obesity and anti-diabetes in mice. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 19-29.	1.2	152
166	New neolignans from the seeds of Myristica fragrans that inhibit nitric oxide production. Food Chemistry, 2015, 173, 231-237.	4.2	67
167	Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. Journal of Clinical Investigation, 2015, 125, 386-402.	3.9	517
168	Forced expression of fibroblast growth factor 21 reverses the sustained impairment of liver regeneration in hPPARÎ±PAC mice due to dysregulated bile acid synthesis. Oncotarget, 2015, 6, 9686-9700.	0.8	11
169	Wuzhi Tablet (Schisandra Sphenanthera Extract) Protects against Acetaminophen-Induced Hepatotoxicity by Inhibition of CYP-Mediated Bioactivation and Regulation of NRF2-ARE and p53/p21 Pathways. Drug Metabolism and Disposition, 2014, 42, 1982-1990.	1.7	55
170	Hepatic oxidative stress activates theGadd45bgene by way of degradation of the transcriptional repressor STAT3. Hepatology, 2014, 59, 695-704.	3.6	52
171	N-methylnicotinamide and nicotinamide N-methyltransferase are associated with microRNA-1291-altered pancreatic carcinoma cell metabolome and suppressed tumorigenesis. Carcinogenesis, 2014, 35, 2264-2272.	1.3	51
172	PPARÎ±-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis. Nature Communications, 2014, 5, 4573.	5.8	122
173	Potential Role of the Vitamin D Receptor in Control of Cholesterol Levels. Gastroenterology, 2014, 146, 899-902.	0.6	11
174	Biomarkers of Coordinate Metabolic Reprogramming in Colorectal Tumors in Mice and Humans. Gastroenterology, 2014, 146, 1313-1324.	0.6	73
175	Role of human pregnane X receptor in high fat diet-induced obesity in pre-menopausal female mice. Biochemical Pharmacology, 2014, 89, 399-412.	2.0	32
176	Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPARÎ± and its relevance to hepatotoxicity. Archives of Toxicology, 2014, 88, 983-996.	1.9	42
177	Chronic ethanol consumption decreases serum sulfatide levels by suppressing hepatic cerebroside sulfotransferase expression in mice. Archives of Toxicology, 2014, 88, 367-379.	1.9	14
178	Altered Expression of Small Heterodimer Partner Governs Cytochrome P450 (CYP) 2D6 Induction during Pregnancy in CYP2D6-humanized Mice. Journal of Biological Chemistry, 2014, 289, 3105-3113.	1.6	48
179	Role of Myc in hepatocellular proliferation and hepatocarcinogenesis. Journal of Hepatology, 2014, 60, 331-338.	1.8	64
180	In vivo effects of the pure aryl hydrocarbon receptor antagonist <scp>GNF</scp>â€351 after oral administration are limited to the gastrointestinal tract. British Journal of Pharmacology, 2014, 171, 1735-1746.	2.7	28

#	Article	IF	Citations
181	Activation of Intestinal Human Pregnane X Receptor Protects against Azoxymethane/Dextran Sulfate Sodiumâ€“Induced Colon Cancer. Journal of Pharmacology and Experimental Therapeutics, 2014, 351, 559-567.	1.3	21
182	Saikosaponin d protects against acetaminophen-induced hepatotoxicity by inhibiting NF-ÎºB and STAT3 signaling. Chemico-Biological Interactions, 2014, 223, 80-86.	1.7	64
183	Role of Pregnane X Receptor in Obesity and Glucose Homeostasis in Male Mice. Journal of Biological Chemistry, 2014, 289, 3244-3261.	1.6	72
184	Estrogen Metabolism by Cytochrome P450 1B1 Modulates the Hypertensive Effect of Angiotensin II in Female Mice. Hypertension, 2014, 64, 134-140.	1.3	50
185	Role of white adipose lipolysis in the development of NASH induced by methionine- and choline-deficient diet. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 1596-1607.	1.2	60
186	Intestinal CYP3A4 protects against lithocholic acid-induced hepatotoxicity in intestine-specific VDR-deficient mice. Journal of Lipid Research, 2014, 55, 455-465.	2.0	55
187	PPARÎ±-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate. American Journal of Physiology - Renal Physiology, 2014, 307, G564-G573.	1.6	35
188	Improved drug therapy: triangulating phenomics with genomics and metabolomics. Human Genomics, 2014, 8, 16.	1.4	26
189	Lipidomics Reveals a Link between CYP1B1 and SCD1 in Promoting Obesity. Journal of Proteome Research, 2014, 13, 2679-2687.	1.8	46
190	LCâ€“MS-based metabolomics: an update. Archives of Toxicology, 2014, 88, 1491-1502.	1.9	75
191	Hypoxia-Inducible Factor/MAZ-Dependent Induction of Caveolin-1 Regulates Colon Permeability through Suppression of Occludin, Leading to Hypoxia-Induced Inflammation. Molecular and Cellular Biology, 2014, 34, 3013-3023.	1.1	59
192	Metabolic profiling of praziquantel enantiomers. Biochemical Pharmacology, 2014, 90, 166-178.	2.0	40
193	Hepatic sirtuin 1 is dispensable for fibrate-induced peroxisome proliferator-activated receptor-Î± function in vivo. American Journal of Physiology - Endocrinology and Metabolism, 2014, 306, E824-E837.	1.8	6
194	Metabolomics reveals trichloroacetate as a major contributor to trichloroethylene-induced metabolic alterations in mouse urine and serum. Archives of Toxicology, 2013, 87, 1975-1987.	1.9	21
195	Hypoxia-inducible Factor 1Î± Regulates a SOCS3-STAT3-Adiponectin Signal Transduction Pathway in Adipocytes. Journal of Biological Chemistry, 2013, 288, 3844-3857.	1.6	61
196	CYP2E1-dependent elevation of serum cholesterol, triglycerides, and hepatic bile acids by isoniazid. Toxicology and Applied Pharmacology, 2013, 266, 245-253.	1.3	53
197	Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nature Communications, 2013, 4, 2384.	5.8	549
198	Regulation of Cyclic AMP Response Element Binding and Hippocampal Plasticity-Related Genes by Peroxisome Proliferator-Activated Receptor Î±. Cell Reports, 2013, 4, 724-737.	2.9	130

#	Article	IF	Citations
199	Exposure to DEHP decreased four fatty acid levels in plasma of prepartum mice. Toxicology, 2013, 309, 52-60.	2.0	24
200	CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis. Free Radical Biology and Medicine, 2013, 65, 1238-1245.	1.3	169
201	FXR signaling in the enterohepatic system. Molecular and Cellular Endocrinology, 2013, 368, 17-29.	1.6	285
202	Stable Isotope- and Mass Spectrometry-based Metabolomics as Tools in Drug Metabolism: A Study Expanding Tempol Pharmacology. Journal of Proteome Research, 2013, 12, 1369-1376.	1.8	29
203	Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nature Medicine, 2013, 19, 418-420.	15.2	130
204	Potential role of CYP2D6 in the central nervous system. Xenobiotica, 2013, 43, 973-984.	0.5	58
205	Disruption of Thioredoxin Reductase 1 Protects Mice from Acute Acetaminophen-Induced Hepatotoxicity through Enhanced NRF2 Activity. Chemical Research in Toxicology, 2013, 26, 1088-1096.	1.7	53
206	Implication of intestinal VDR deficiency in inflammatory bowel disease. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 2118-2128.	1.1	60
207	The aryl hydrocarbon receptor and glucocorticoid receptor interact to activate human metallothionein 2A. Toxicology and Applied Pharmacology, 2013, 273, 90-99.	1.3	37
208	A model of in vitro UDP-glucuronosyltransferase inhibition by bile acids predicts possible metabolic disorders. Journal of Lipid Research, 2013, 54, 3334-3344.	2.0	29
209	Metabolomics Reveals That Tumor Xenografts Induce Liver Dysfunction. Molecular and Cellular Proteomics, 2013, 12, 2126-2135.	2.5	16
210	Targeted Metabolomics of Serum Acylcarnitines Evaluates Hepatoprotective Effect of Wuzhi Tablet (Schisandra sphenantheraExtract) against Acute Acetaminophen Toxicity. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-13.	0.5	35
211	Cytochrome P450 Regulation by Î±-Tocopherol in Pxr-Null and PXR-Humanized Mice. Drug Metabolism and Disposition, 2013, 41, 406-413.	1.7	25
212	Metabolomics. Toxicologic Pathology, 2013, 41, 410-418.	0.9	14
213	Hypoxia-Inducible Factor-1Î± (HIF-1Î±) Potentiates Î²-Cell Survival after Islet Transplantation of Human and Mouse Islets. Cell Transplantation, 2013, 22, 253-266.	1.2	61
214	Global Metabolomics Reveals Urinary Biomarkers of Breast Cancer in a MCF-7 Xenograft Mouse Model. Metabolites, 2013, 3, 658-672.	1.3	18
215	Cytochrome P450 1B1 Contributes to Renal Dysfunction and Damage Caused by Angiotensin II in Mice. Hypertension, 2012, 59, 348-354.	1.3	47
216	Network Analysis of a Pkd1-Mouse Model of Autosomal Dominant Polycystic Kidney Disease Identifies HNF4Î± as a Disease Modifier. PLoS Genetics, 2012, 8, e1003053.	1.5	75

#	Article	IF	Citations
217	Disruption of Endothelial Peroxisome Proliferator-Activated Receptor Î³ Accelerates Diet-Induced Atherogenesis in LDL Receptor-Null Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 65-73.	1.1	38
218	Metabolomics reveals an essential role for peroxisome proliferator-activated receptor Î± in bile acid homeostasis. Journal of Lipid Research, 2012, 53, 1625-1635.	2.0	63
219	Novel metabolites and roles for Î±-tocopherol in humans and mice discovered by mass spectrometryâ€“based metabolomics. American Journal of Clinical Nutrition, 2012, 96, 818-830.	2.2	49
220	Expression and Regulation of Human Fetal-Specific CYP3A7 in Mice. Endocrinology, 2012, 153, 1453-1463.	1.4	19
221	Nuclear Receptor Control of Enterohepatic Circulation. , 2012, 2, 2811-2828.		71
222	Cytochrome P450 1B1 Gene Disruption Minimizes Deoxycorticosterone Acetate-Saltâ€“Induced Hypertension and Associated Cardiac Dysfunction and Renal Damage in Mice. Hypertension, 2012, 60, 1510-1516.	1.3	25
223	Abcb11 Deficiency Induces Cholestasis Coupled to Impaired Î²-Fatty Acid Oxidation in Mice. Journal of Biological Chemistry, 2012, 287, 24784-24794.	1.6	63
224	TGF-Î²-SMAD3 signaling mediates hepatic bile acid and phospholipid metabolism following lithocholic acid-induced liver injury. Journal of Lipid Research, 2012, 53, 2698-2707.	2.0	28
225	Chronic Exposure to Rifaximin Causes Hepatic Steatosis in Pregnane X Receptor-Humanized Mice. Toxicological Sciences, 2012, 129, 456-468.	1.4	35
226	Reply:. Hepatology, 2012, 56, 2009-2009.	3.6	1
227	Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends in Pharmacological Sciences, 2012, 33, 323-330.	4.0	133
228	Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis. Journal of Hepatology, 2012, 57, 860-866.	1.8	204
229	Radiation Metabolomics. 5. Identification of Urinary Biomarkers of Ionizing Radiation Exposure in Nonhuman Primates by Mass Spectrometry-Based Metabolomics. Radiation Research, 2012, 178, 328.	0.7	88
230	Metabolic map and bioactivation of the antiâ€tumour drug noscapine. British Journal of Pharmacology, 2012, 167, 1271-1286.	2.7	53
231	Anks4b, a Novel Target of HNF4Î± Protein, Interacts with GRP78 Protein and Regulates Endoplasmic Reticulum Stress-induced Apoptosis in Pancreatic Î²-Cells. Journal of Biological Chemistry, 2012, 287, 23236-23245.	1.6	27
232	Metabolomics Identifies an Inflammatory Cascade Involved in Dioxin- and Diet-Induced Steatohepatitis. Cell Metabolism, 2012, 16, 634-644.	7.2	76
233	Modulation of Mouse Coagulation Gene Transcription following Acute In Vivo Delivery of Synthetic Small Interfering RNAs Targeting HNF4Î± and C/EBPÎ±. PLoS ONE, 2012, 7, e38104.	1.1	26
234	Suppression of Hepatocyte Proliferation by Hepatocyte Nuclear Factor 4Î± in Adult Mice. Journal of Biological Chemistry, 2012, 287, 7345-7356.	1.6	173

#	Article	IF	Citations
235	Challenges and opportunities of metabolomics. Journal of Cellular Physiology, 2012, 227, 2975-2981.	2.0	211
236	Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology, 2012, 56, 118-129.	3.6	215
237	Peroxisome proliferator-activated receptor alpha induction of uncoupling protein 2 protects against acetaminophen-induced liver toxicity. Hepatology, 2012, 56, 281-290.	3.6	95
238	Xenobiotic Metabolomics: Major Impact on the Metabolome. Annual Review of Pharmacology and Toxicology, 2012, 52, 37-56.	4.2	209
239	The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nature Reviews Cancer, 2012, 12, 181-195.	12.8	379
240	Metabolomics reveals the metabolic map of procainamide in humans and mice. Biochemical Pharmacology, 2012, 83, 1435-1444.	2.0	34
241	Radiation Metabolomics. 4. UPLC-ESI-QTOFMS-Based Metabolomics for Urinary Biomarker Discovery in Gamma-Irradiated Rats. Radiation Research, 2011, 175, 473-484.	0.7	92
242	UPLCâ€“MS-based Urine Metabolomics Reveals Indole-3-lactic Acid and Phenyllactic Acid as Conserved Biomarkers for Alcohol-induced Liver Disease in the Ppara-null Mouse Model. Journal of Proteome Research, 2011, 10, 4120-4133.	1.8	73
243	Aberrant Lipid Metabolism in Hepatocellular Carcinoma Revealed by Plasma Metabolomics and Lipid Profiling. Cancer Research, 2011, 71, 6590-6600.	0.4	243
244	Pregnane X receptor-mediated induction of Cyp3a by black cohosh. Xenobiotica, 2011, 41, 112-123.	0.5	26
245	Humanized Transgenic Mouse Models for Drug Metabolism and Pharmacokinetic Research. Current Drug Metabolism, 2011, 12, 997-1006.	0.7	29
246	Pregnane X receptorâ€•and CYP3A4â€humanized mouse models and their applications. British Journal of Pharmacology, 2011, 163, 461-468.	2.7	37
247	A comprehensive understanding of thioTEPA metabolism in the mouse using UPLCâ€“ESI-QTOFMS-based metabolomics. Biochemical Pharmacology, 2011, 81, 1043-1053.	2.0	32
248	Lithocholic acid disrupts phospholipid and sphingolipid homeostasis leading to cholestasis in mice. Hepatology, 2011, 53, 1282-1293.	3.6	86
249	The stable repression of mesenchymal program is required for hepatocyte identity: A novel role for hepatocyte nuclear factor 4Î±. Hepatology, 2011, 53, 2063-2074.	3.6	116
250	Hypoxia-inducible transcription factor 2Î± promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis. Hepatology, 2011, 54, 472-483.	3.6	147
251	Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity. Diabetes, 2011, 60, 1861-1871.	0.3	261
252	PPARÎ± Expression Protects Male Mice from High Fatâ€“Induced Nonalcoholic Fatty Liver1â€“3. Journal of Nutrition, 2011, 141, 603-610.	1.3	224

#	Article	IF	Citations
253	Thermogenic Activation Induces FGF21 Expression and Release in Brown Adipose Tissue. Journal of Biological Chemistry, 2011, 286, 12983-12990.	1.6	512
254	Transgenic Animal Models in Toxicology: Historical Perspectives and Future Outlook. Toxicological Sciences, 2011, 121, 207-233.	1.4	88
255	Disruption of Hypoxia-Inducible Factor 1 in Adipocytes Improves Insulin Sensitivity and Decreases Adiposity in High-Fat Dietâ€“Fed Mice. Diabetes, 2011, 60, 2484-2495.	0.3	241
256	Metabolomics Reveals Attenuation of the SLC6A20 Kidney Transporter in Nonhuman Primate and Mouse Models of Type 2 Diabetes Mellitus. Journal of Biological Chemistry, 2011, 286, 19511-19522.	1.6	78
257	Xenobiotic Metabolism: A View through the Metabolometer. Chemical Research in Toxicology, 2010, 23, 851-860.	1.7	88
258	Role of cytochrome P450 2E1 in protein nitration and ubiquitin-mediated degradation during acetaminophen toxicity. Biochemical Pharmacology, 2010, 79, 57-66.	2.0	72
259	Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLCâ€“ESI-QTOFMS-based metabolomics. Biochemical Pharmacology, 2010, 80, 1063-1074.	2.0	54
260	Eicosapentaenoic acid improves hepatic steatosis independent of PPARÎ± activation through inhibition of SREBP-1 maturation in mice. Biochemical Pharmacology, 2010, 80, 1601-1612.	2.0	66
261	Urinary metabolomics in Fxr-null mice reveals activated adaptive metabolic pathways upon bile acid challenge. Journal of Lipid Research, 2010, 51, 1063-1074.	2.0	41
262	PPARÎ±-Dependent Activation of Cell Cycle Control and DNA Repair Genes in Hepatic Nonparenchymal Cells. Toxicological Sciences, 2010, 118, 404-410.	1.4	28
263	Therapeutic Role of Rifaximin in Inflammatory Bowel Disease: Clinical Implication of Human Pregnane X Receptor Activation. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 32-41.	1.3	144
264	Control of Steroid 21-oic Acid Synthesis by Peroxisome Proliferator-activated Receptor Î± and Role of the Hypothalamic-Pituitary-Adrenal Axis. Journal of Biological Chemistry, 2010, 285, 7670-7685.	1.6	19
265	Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model. Diabetes, 2010, 59, 2916-2927.	0.3	149
266	Hepatocyte Nuclear Factor 4Î± Coordinates a Transcription Factor Network Regulating Hepatic Fatty Acid Metabolism. Molecular and Cellular Biology, 2010, 30, 565-577.	1.1	132
267	Identification of Novel Pathways That Control Farnesoid X Receptor-mediated Hypocholesterolemia. Journal of Biological Chemistry, 2010, 285, 3035-3043.	1.6	96
268	Differential Response to Trichloroethylene-Induced Hepatosteatosis in Wild-Type and PPARÎ±-Humanized Mice. Environmental Health Perspectives, 2010, 118, 1557-1563.	2.8	36
269	Cytochrome P450 1B1 Contributes to Angiotensin IIâ€“Induced Hypertension and Associated Pathophysiology. Hypertension, 2010, 56, 667-674.	1.3	58
270	Metabolomics Identifies Novel Hnf1Î±-Dependent Physiological Pathways in Vivo. Molecular Endocrinology, 2010, 24, 2343-2355.	3.7	23

#	Article	IF	Citations
271	A Novel Role for the Dioxin Receptor in Fatty Acid Metabolism and Hepatic Steatosis. Gastroenterology, 2010, 139, 653-663.	0.6	228
272	Alterations in Hepatic mRNA Expression of Phase II Enzymes and Xenobiotic Transporters after Targeted Disruption of Hepatocyte Nuclear Factor 4 Alpha. Toxicological Sciences, 2010, 118, 380-390.	1.4	47
273	Identification of Noninvasive Biomarkers for Alcohol-Induced Liver Disease Using Urinary Metabolomics and the Ppara-null Mouse. Journal of Proteome Research, 2010, 9, 4176-4188.	1.8	57
274	Hypoxia-inducible factor-1Î± regulates Î² cell function in mouse and human islets. Journal of Clinical Investigation, 2010, 120, 2171-2183.	3.9	191
275	Fenofibrate Metabolism in the Cynomolgus Monkey using Ultraperformance Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometry-Based Metabolomics. Drug Metabolism and Disposition, 2009, 37, 1157-1163.	1.7	30
276	Rifampicin-Activated Human Pregnane X Receptor and CYP3A4 Induction Enhance Acetaminophen-Induced Toxicity. Drug Metabolism and Disposition, 2009, 37, 1611-1621.	1.7	111
277	The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. American Journal of Physiology - Renal Physiology, 2009, 297, F1587-F1596.	1.3	147
278	Farnesoid X Receptor Deficiency in Mice Leads to Increased Intestinal Epithelial Cell Proliferation and Tumor Development. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 469-477.	1.3	198
279	Role of peroxisome proliferator-activated receptor-Î± in fasting-mediated oxidative stress. Free Radical Biology and Medicine, 2009, 47, 767-778.	1.3	70
280	Serum Metabolomics Reveals Irreversible Inhibition of Fatty Acid Î²-Oxidation through the Suppression of PPARÎ± Activation as a Contributing Mechanism of Acetaminophen-Induced Hepatotoxicity. Chemical Research in Toxicology, 2009, 22, 699-707.	1.7	159
281	Intestinal Hypoxia-Inducible Transcription Factors Are Essential for Iron Absorption following Iron Deficiency. Cell Metabolism, 2009, 9, 152-164.	7.2	353
282	Ablation of ARNT/HIF1Î² in Liver Alters Gluconeogenesis, Lipogenic Gene Expression, and Serum Ketones. Cell Metabolism, 2009, 9, 428-439.	7.2	76
283	Polyenephosphatidylcholine prevents alcoholic liver disease in PPARÎ±-null mice through attenuation of increases in oxidative stress. Journal of Hepatology, 2009, 50, 1236-1246.	1.8	84
284	Radiation Metabolomics. 3. Biomarker Discovery in the Urine of Gamma-Irradiated Rats Using a Simplified Metabolomics Protocol of Gas Chromatography-Mass Spectrometry Combined with Random Forests Machine Learning Algorithm. Radiation Research, 2009, 172, 198-212.	0.7	94
285	Radiation Metabolomics. 2. Dose- and Time-Dependent Urinary Excretion of Deaminated Purines and Pyrimidines after Sublethal Gamma-Radiation Exposure in Mice. Radiation Research, 2009, 172, 42-57.	0.7	109
286	Human Urinary Metabolomic Profile of PPARÎ± Induced Fatty Acid Î²-Oxidation. Journal of Proteome Research, 2009, 8, 4293-4300.	1.8	55
287	PPARÎ±: Mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology, 2008, 246, 2-8.	2.0	256
288	Low-dose dioxins alter gene expression related to cholesterol biosynthesis, lipogenesis, and glucose metabolism through the aryl hydrocarbon receptor-mediated pathway in mouse liver. Toxicology and Applied Pharmacology, 2008, 229, 10-19.	1.3	121

#	Article	IF	Citations
289	Molecular mechanism of trichloroethylene-induced hepatotoxicity mediated by CYP2E1. Toxicology and Applied Pharmacology, 2008, 231, 300-307.	1.3	47
290	Hypoxia-Inducible Factor Augments Experimental Colitis Through an MIFâ€“Dependent Inflammatory Signaling Cascade. Gastroenterology, 2008, 134, 2036-2048.e3.	0.6	146
291	Role of CYP1B1 in Glaucoma. Annual Review of Pharmacology and Toxicology, 2008, 48, 333-358.	4.2	165
292	Metabolomics Reveals that Hepatic Stearoyl-CoA Desaturase 1 Downregulation ExacerbatesÂInflammation and Acute Colitis. Cell Metabolism, 2008, 7, 135-147.	7.2	144
293	Hepatic Steatosis in Leptin-Deficient Mice Is Promoted by the PPARÎ³ Target Gene Fsp27. Cell Metabolism, 2008, 7, 302-311.	7.2	294
294	A Metabolomic Perspective of Melatonin Metabolism in the Mouse. Endocrinology, 2008, 149, 1869-1879.	1.4	60
295	Humanized Mouse Lines and Their Application for Prediction of Human Drug Metabolism and Toxicological Risk Assessment. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 288-299.	1.3	126
296	UPLC-ESI-TOFMS-Based Metabolomics and Gene Expression Dynamics Inspector Self-Organizing Metabolomic Maps as Tools for Understanding the Cellular Response to Ionizing Radiation. Analytical Chemistry, 2008, 80, 665-674.	3.2	142
297	Identification of Novel Toxicity-associated Metabolites by Metabolomics and Mass Isotopomer Analysis of Acetaminophen Metabolism in Wild-type and Cyp2e1-null Mice. Journal of Biological Chemistry, 2008, 283, 4543-4559.	1.6	124
298	A Double Transgenic Mouse Model Expressing Human Pregnane X Receptor and Cytochrome P450 3A4. Drug Metabolism and Disposition, 2008, 36, 2506-2512.	1.7	56
299	The PPARÎ±-Humanized Mouse: A Model to Investigate Species Differences in Liver Toxicity Mediated by PPARÎ±. Toxicological Sciences, 2008, 101, 132-139.	1.4	152
300	Regulation of Hepatocyte Nuclear Factor 4Î±-mediated Transcription. Drug Metabolism and Pharmacokinetics, 2008, 23, 2-7.	1.1	171
301	PPARÎ± activation is essential for HCV core proteinâ€“induced hepatic steatosis and hepatocellular carcinoma in mice. Journal of Clinical Investigation, 2008, 118, 683-94.	3.9	194
302	Phenotype of theCyp1a1/1a2/1b1(-/-) Triple-Knockout Mouse. Molecular Pharmacology, 2008, 73, 1844-1856.	1.0	61
303	Cytochrome P450 Expression and Regulation in CYP3A4/CYP2D6 Double Transgenic Humanized Mice. Drug Metabolism and Disposition, 2008, 36, 435-441.	1.7	53
304	The pregnane X receptor: from bench to bedside. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 895-908.	1.5	113
305	Radiation Metabolomics. 1. Identification of Minimally Invasive Urine Biomarkers for Gamma-Radiation Exposure in Mice. Radiation Research, 2008, 170, 1-14.	0.7	151
306	Peroxisome Proliferator-Activated Receptor Î± Regulates a MicroRNA-Mediated Signaling Cascade Responsible for Hepatocellular Proliferation. Molecular and Cellular Biology, 2007, 27, 4238-4247.	1.1	264

#	Article	IF	Citations
307	CYP2E1. Drug Metabolism and Disposition, 2007, 35, 1-8.	1.7	198
308	The Pregnane X Receptor Gene-Humanized Mouse: A Model for Investigating Drug-Drug Interactions Mediated by Cytochromes P450 3A. Drug Metabolism and Disposition, 2007, 35, 194-200.	1.7	131
309	Hepatocyte-restricted constitutive activation of PPARÂ induces hepatoproliferation but not hepatocarcinogenesis. Carcinogenesis, 2007, 28, 1171-1177.	1.3	44
310	Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-ÍºB target gene expression. American Journal of Physiology - Renal Physiology, 2007, 292, G1114-G1122.	1.6	202
311	Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis, 2007, 28, 940-946.	1.3	328
312	Metabolomic and Genetic Analysis of Biomarkers for Peroxisome Proliferator-Activated Receptor Î± Expression and Activation. Molecular Endocrinology, 2007, 21, 2136-2151.	3.7	79
313	Cooperative Interaction between Hepatocyte Nuclear Factor 4Î± and GATA Transcription Factors Regulates ATP-Binding Cassette Sterol Transporters ABCG5 and ABCG8. Molecular and Cellular Biology, 2007, 27, 4248-4260.	1.1	88
314	LC-MS-Based Metabolomics in Drug Metabolism. Drug Metabolism Reviews, 2007, 39, 581-597.	1.5	242
315	Metabolomics. Cell Metabolism, 2007, 6, 348-351.	7.2	199
316	Rifaximin Is a Gut-Specific Human Pregnane X Receptor Activator. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 391-398.	1.3	109
317	Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. Journal of Lipid Research, 2007, 48, 2664-2672.	2.0	473
318	CYP3A4 and pregnane X receptor humanized mice. Journal of Biochemical and Molecular Toxicology, 2007, 21, 158-162.	1.4	36
319	The metabolomics of (Â±)-arecoline 1-oxide in the mouse and its formation by human flavin-containing monooxygenases. Biochemical Pharmacology, 2007, 73, 561-573.	2.0	61
320	A Comprehensive Investigation of 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) Metabolism in the Mouse Using a Multivariate Data Analysis Approach. Chemical Research in Toxicology, 2007, 20, 531-542.	1.7	64
321	Animal Models for Human Risk Assessment: The Peroxisome Proliferator-Activated Receptor Alpha-Humanized Mouse. Nutrition Reviews, 2007, 65, S2-S6.	2.6	8
322	Animal Models for Human Risk Assessment: The Peroxisome Proliferator-Activated Receptor Alpha-Humanized Mouse. Nutrition Reviews, 2007, 65, 2-6.	2.6	15
323	Oral Benzo[a]pyrene in Cyp1 Knockout Mouse Lines: CYP1A1 Important in Detoxication, CYP1B1 Metabolism Required for Immune Damage Independent of Total-Body Burden and Clearance Rate. Molecular Pharmacology, 2006, 69, 1103-1114.	1.0	211
324	A Metabolomic Approach to the Metabolism of the Areca Nut Alkaloids Arecoline and Arecaidine in the Mouse. Chemical Research in Toxicology, 2006, 19, 818-827.	1.7	140

#	Article	IF	Citations
325	Effects of FXR in foam-cell formation and atherosclerosis development. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2006, 1761, 1401-1409.	1.2	110
326	Chenodeoxycholic Acid-mediated Activation of the Farnesoid X Receptor Negatively Regulates Hydroxysteroid Sulfotransferase. Drug Metabolism and Pharmacokinetics, 2006, 21, 315-323.	1.1	32
327	Urinary metabolites and antioxidant products of exogenous melatonin in the mouse. Journal of Pineal Research, 2006, 40, 343-349.	3.4	55
328	Role of hepatocyte nuclear factor 4Î± in control of blood coagulation factor gene expression. Journal of Molecular Medicine, 2006, 84, 334-344.	1.7	55
329	Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor Î± to Wy-14,643-induced liver tumorigenesis. Carcinogenesis, 2006, 27, 1074-1080.	1.3	162
330	Regulation of Mouse Hepatic Î±-Amino-Î²-Carboxymuconate-Ï‰-Semialdehyde Decarboxylase, a Key Enzyme in the Tryptophan-Nicotinamide Adenine Dinucleotide Pathway, by Hepatocyte Nuclear Factor 4Î± and Peroxisome Proliferator-Activated Receptor Î±. Molecular Pharmacology, 2006, 70, 1281-1290.	1.0	34
331	FXR regulates organic solute transporters Î± and Î² in the adrenal gland, kidney, and intestine. Journal of Lipid Research, 2006, 47, 201-214.	2.0	153
332	Regulation of bile acid biosynthesis by hepatocyte nuclear factor 4Î±. Journal of Lipid Research, 2006, 47, 215-227.	2.0	121
333	The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice. Journal of Biological Chemistry, 2006, 281, 11039-11049.	1.6	463
334	Regulation of Constitutive Androstane Receptor and Its Target Genes by Fasting, cAMP, Hepatocyte Nuclear Factor Î±, and the Coactivator Peroxisome Proliferator-activated Receptor Î³ Coactivator-1Î±. Journal of Biological Chemistry, 2006, 281, 26540-26551.	1.6	131
335	Growth Hormone Determines Sexual Dimorphism of Hepatic Cytochrome P450 3A4 Expression in Transgenic Mice. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 1328-1334.	1.3	84
336	Hepatocyte Nuclear Factor-4Î± Is Essential for Glucose-stimulated Insulin Secretion by Pancreatic Î²-Cells. Journal of Biological Chemistry, 2006, 281, 5246-5257.	1.6	148
337	Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1006-1011.	3.3	806
338	International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors. Pharmacological Reviews, 2006, 58, 726-741.	7.1	869
339	Urinary Metabolite Profiling Reveals CYP1A2-Mediated Metabolism of NSC686288 (Aminoflavone). Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 1330-1342.	1.3	62
340	METABOLISM OF MELATONIN BY HUMAN CYTOCHROMES P450. Drug Metabolism and Disposition, 2005, 33, 489-494.	1.7	274
341	Peroxisome proliferator-activated receptor-Î± and liver cancer: where do we stand?. Journal of Molecular Medicine, 2005, 83, 774-785.	1.7	229
342	HUMAN CYP2D6 AND MOUSE CYP2DS: ORGAN DISTRIBUTION IN A HUMANIZED MOUSE MODEL. Drug Metabolism and Disposition, 2005, 33, 1495-1502.	1.7	45

#	Article	IF	Citations
343	Hepatic Expression of the UGT1A9 Gene Is Governed by Hepatocyte Nuclear Factor 4Î±. Molecular Pharmacology, 2005, 67, 241-249.	1.0	61
344	Role of Farnesoid X Receptor in the Enhancement of Canalicular Bile Acid Output and Excretion of Unconjugated Bile Acids: A Mechanism for Protection against Cholic Acid-Induced Liver Toxicity. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 759-766.	1.3	29
345	Potential Role for Human Cytochrome P450 3A4 in Estradiol Homeostasis. Endocrinology, 2005, 146, 2911-2919.	1.4	73
346	THECYP2E1-HUMANIZED TRANSGENIC MOUSE: ROLE OF CYP2E1 IN ACETAMINOPHEN HEPATOTOXICITY. Drug Metabolism and Disposition, 2005, 33, 449-457.	1.7	156
347	Differential Metabolism of 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in Mice Humanized forCYP1A1andCYP1A2. Chemical Research in Toxicology, 2005, 18, 1471-1478.	1.7	94
348	Loss of ARNT/HIF1Î² Mediates Altered Gene Expression and Pancreatic-Islet Dysfunction in Human Type 2 Diabetes. Cell, 2005, 122, 337-349.	13.5	460
349	Hepatocyte Nuclear Factor 4Î± Is a Central Regulator of Bile Acid Conjugation. Journal of Biological Chemistry, 2004, 279, 2480-2489.	1.6	90
350	Progressive Glomerulonephritis and Histiocytic Sarcoma Associated with Macrophage Functional Defects in CYP1B1-Deficient Mice. Toxicologic Pathology, 2004, 32, 710-718.	0.9	31
351	Diminished Hepatocellular Proliferation in Mice Humanized for the Nuclear Receptor Peroxisome Proliferator-Activated Receptor Î±. Cancer Research, 2004, 64, 3849-3854.	0.4	194
352	Role of peroxisome proliferator-activated receptor-Â (PPARÂ) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis, 2004, 26, 219-227.	1.3	119
353	Enhanced Acetaminophen Toxicity by Activation of the Pregnane X Receptor. Toxicological Sciences, 2004, 82, 374-380.	1.4	95
354	Regulation of Drug Transporters by the Farnesoid X Receptor in Mice. Molecular Pharmaceutics, 2004, 1, 281-289.	2.3	30
355	Hepatic CCAAT/Enhancer Binding Protein Î± Mediates Induction of Lipogenesis and Regulation of Glucose Homeostasis in Leptin-Deficient Mice. Molecular Endocrinology, 2004, 18, 2751-2764.	3.7	78
356	Polymorphic Cytochrome P450 2D6: Humanized Mouse Model and Endogenous Substrates. Drug Metabolism Reviews, 2004, 36, 243-277.	1.5	111
357	Hepatocyte nuclear factors 1Î± and 4Î± control expression of proline oxidase in adult liver. FEBS Letters, 2004, 578, 63-68.	1.3	13
358	Role of Aryl Hydrocarbon Receptor-mediated Induction of the CYP1 Enzymes in Environmental Toxicity and Cancer. Journal of Biological Chemistry, 2004, 279, 23847-23850.	1.6	1,018
359	Peroxisome proliferator-activated receptor ? protects against alcohol-induced liver damage. Hepatology, 2004, 40, 972-980.	3.6	214
360	Role of the hepatocyte nuclear factor 4Î± in control of the pregnane X receptor during fetal liver development. Hepatology, 2003, 37, 1375-1384.	3.6	129

#	Article	IF	Citations
361	The orphan nuclear receptor HNF4Î± determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nature Medicine, 2003, 9, 220-224.	15.2	418
362	Modification of Ocular Defects in Mouse Developmental Glaucoma Models by Tyrosinase. Science, 2003, 299, 1578-1581.	6.0	216
363	Liver Peroxisome Proliferator-activated Receptor Î³ Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass. Journal of Biological Chemistry, 2003, 278, 34268-34276.	1.6	672
364	Liver Receptor Homologue-1 Mediates Species- and Cell Line-specific Bile Acid-dependent Negative Feedback Regulation of the Apical Sodium-dependent Bile Acid Transporter. Journal of Biological Chemistry, 2003, 278, 19909-19916.	1.6	211
365	Contribution of Individual Cytochrome P450 Isozymes to theO-Demethylation of the Psychotropic Î²-Carboline Alkaloids Harmaline and Harmine. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 315-322.	1.3	117
366	CYP1B1 determines susceptibility to low doses of 7,12-dimethylbenz[a]anthracene-induced ovarian cancers in mice: correlation of CYP1B1-mediated DNA adducts with carcinogenicity. Carcinogenesis, 2003, 24, 327-334.	1.3	106
367	Expression of the Human CYP3A4 Gene in the Small Intestine of Transgenic Mice: In Vitro Metabolism and Pharmacokinetics of Midazolam. Drug Metabolism and Disposition, 2003, 31, 548-558.	1.7	101
368	Regulation of hepatic fasting response by PPARÂ coactivator-1Â (PGC-1): Requirement for hepatocyte nuclear factor 4Â in gluconeogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4012-4017.	3.3	522
369	Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics and Genomics, 2003, 13, 173-81.	5.7	69
370	Defective Ureagenesis in Mice Carrying a Liver-specific Disruption of Hepatocyte Nuclear Factor 4Î± (HNF4Î±). Journal of Biological Chemistry, 2002, 277, 25257-25265.	1.6	95
371	The Coactivator PGC-1 Is Involved in the Regulation of the Liver Carnitine Palmitoyltransferase I Gene Expression by cAMP in Combination with HNF4Î± and cAMP-response Element-binding Protein (CREB). Journal of Biological Chemistry, 2002, 277, 37991-38000.	1.6	138
372	Cytochrome P450 1B1 Determines Susceptibility to Dibenzo[a,l]pyrene-Induced Tumor Formation. Chemical Research in Toxicology, 2002, 15, 1127-1135.	1.7	96
373	A Natural Product That Lowers Cholesterol As an Antagonist Ligand for FXR. Science, 2002, 296, 1703-1706.	6.0	491
374	Conditional Disruption of the Peroxisome Proliferator-Activated Receptor Î³ Gene in Mice Results in Lowered Expression of ABCA1, ABCG1, and apoE in Macrophages and Reduced Cholesterol Efflux. Molecular and Cellular Biology, 2002, 22, 2607-2619.	1.1	357
375	Influence of conjugated linoleic acid on body composition and target gene expression in peroxisome proliferator-activated receptor Î±-null mice. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2001, 1533, 233-242.	1.2	131
376	The CYP2D6 Humanized Mouse: Effect of the HumanCYP2D6 Transgene and HNF4Î± on the Disposition of Debrisoquine in the Mouse. Molecular Pharmacology, 2001, 60, 1260-1267.	1.0	142
377	Antagonism of the Actions of Peroxisome Proliferator-activated Receptor-Î± by Bile Acids. Journal of Biological Chemistry, 2001, 276, 47154-47162.	1.6	65
378	Peroxisome Proliferator-activated Receptor-Î± Regulates Lipid Homeostasis, but Is Not Associated with Obesity. Journal of Biological Chemistry, 2001, 276, 39088-39093.	1.6	119

#	Article	IF	Citations
379	Disrupted Bile Acid Homeostasis Reveals an Unexpected Interaction among Nuclear Hormone Receptors, Transporters, and Cytochrome P450. Journal of Biological Chemistry, 2001, 276, 39411-39418.	1.6	343
380	Hepatocyte Nuclear Factor 4Î± (Nuclear Receptor 2A1) Is Essential for Maintenance of Hepatic Gene Expression and Lipid Homeostasis. Molecular and Cellular Biology, 2001, 21, 1393-1403.	1.1	998
381	CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity. Clinical Pharmacology and Therapeutics, 2000, 67, 48-56.	2.3	286
382	Peroxisome proliferator-activated receptor Â is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. Carcinogenesis, 2000, 21, 823-826.	1.3	122
383	Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis. Cell, 2000, 102, 731-744.	13.5	1,604
384	Conditional Disruption of the Aryl Hydrocarbon Receptor Nuclear Translocator (Arnt) Gene Leads to Loss of Target Gene Induction by the Aryl Hydrocarbon Receptor and Hypoxia-Inducible Factor 1Î±. Molecular Endocrinology, 2000, 14, 1674-1681.	3.7	115
385	Effect of Peroxisome Proliferator-Activated Receptor Alpha Activators on Tumor Necrosis Factor Expression in Mice during Endotoxemia. Infection and Immunity, 1999, 67, 3488-3493.	1.0	77
386	Peroxisome proliferatorâ€“activated receptor Î± mediates the adaptive response to fasting. Journal of Clinical Investigation, 1999, 103, 1489-1498.	3.9	1,423
387	Protection against Acetaminophen Toxicity in CYP1A2 and CYP2E1 Double-Null Mice. Toxicology and Applied Pharmacology, 1998, 152, 193-199.	1.3	288
388	Altered Constitutive Expression of Fatty Acid-metabolizing Enzymes in Mice Lacking the Peroxisome Proliferator-activated Receptor Î± (PPARÎ±). Journal of Biological Chemistry, 1998, 273, 5678-5684.	1.6	777
389	Role of CYP2E1 in the Hepatotoxicity of Acetaminophen. Journal of Biological Chemistry, 1996, 271, 12063-12067.	1.6	557
390	Aryl-hydrocarbon Receptor-Deficient Mice Are Resistant to 2,3,7,8-Tetrachlorodibenzo-p-dioxin-Induced Toxicity. Toxicology and Applied Pharmacology, 1996, 140, 173-179.	1.3	762
391	CYP2C11 and CYP2B1 are major cytochrome P450 forms involved in styrene oxidation in liver and lung microsomes from untreated rats, respectively. Biochemical Pharmacology, 1994, 48, 637-642.	2.0	48
392	Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chemical Research in Toxicology, 1993, 6, 511-518.	1.7	381
393	cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry, 1993, 32, 5598-5604.	1.2	499
394	Molecular genetics of the debrisoquin-sparteine polymorphism. Clinical Pharmacology and Therapeutics, 1991, 50, 233-238.	2.3	131
395	Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clinical Pharmacology and Therapeutics, 1989, 46, 521-527.	2.3	254
396	Stabilization of Cytochrome P450j Messenger Ribonucleic Acid in the Diabetic Rat. Molecular Endocrinology, 1987, 1, 542-547.	3.7	200

#	Article	IF	Citations
397	Activation of PPARÎ± Stimulates Hippocampal Neurogenesis. SSRN Electronic Journal, 0, , .	0.4	0